Strata Critical Medical, Inc. (SRTA)

Strata Critical Medical, Inc. (SRTA) — VMCI valuation read

Strata Critical Medical, Inc. (SRTA) carries a VMCI composite of 51/100, 1 points above the Industrials sector median of 50. Among mid-cap names, that gap places SRTA in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The SRTA insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads SRTA trades at 26.0x earnings, 44% above the Industrials median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Industrials 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Industrials median (10.0%). Risk: net debt to EBITDA of -0.6x leaves covenant headroom, the line to track on Strata Critical Medical, Inc.'s next 10-Q.

SRTA rose 0.7% over the trailing 7 days, with a -22.8% read on a 30-day basis.